Clinical trial
Randomized, Multicenter, Phase II/III Study, Evaluating Fractionated Cisplatin Chemotherapy/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.
NCT02240017 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Multicenter, Phase II/III Study, Evaluating Fractionated Cisplatin Chemotherapy/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.
- Lead sponsor
- Institut Claudius Regaud
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- January 21, 2015
- Completion date
- July 15, 2019
- Enrollment
- 46 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.
advanced urothelial cancer, metastatic urothelial cancer